Purple Biotech Ltd.
Develops cancer therapies to overcome tumor immune evasion and drug resistance.
PPBT | TA
Overview
Corporate Details
- ISIN(s):
- IL0007650166
- LEI:
- Country:
- Israel
- Address:
- Oppenheimer 4, 7670104 Rehovot
- Website:
- https://purple-biotech.com/
- Sector:
- Manufacturing
Description
Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-19 01:33 |
FORM 6-K- Annual General Meeting of Shareholders will be held on August 25, 2022
|
English | 36.6 KB | ||
| 2022-07-14 16:39 |
6K:Purple Biotech Announces Executive Leadership Changes
|
English | 166.3 KB | ||
| 2022-07-14 16:39 |
6K:Purple Biotech Announces Executive Leadership Changes
|
English | 36.3 KB | ||
| 2022-06-06 16:42 |
Company Presentation – June 2022
|
English | 3.9 MB | ||
| 2022-06-06 16:42 |
Company Presentation – June 2022
|
English | 36.2 KB | ||
| 2022-05-29 17:11 |
6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2…
|
English | 175.8 KB | ||
| 2022-05-29 17:11 |
6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2…
|
English | 36.5 KB | ||
| 2022-05-29 11:58 |
A report regarding phase 1 interim monotherapy data for NT219 was published on …
|
Hebrew (modern) | 89.9 KB | ||
| 2022-05-18 17:40 |
6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
|
English | 157.0 KB | ||
| 2022-05-18 17:40 |
6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
|
English | 36.3 KB | ||
| 2022-05-12 17:25 |
6K: Purple Biotech Reports First Quarter 2022 Financial Results
|
English | 155.0 KB | ||
| 2022-05-12 17:25 |
6K: Purple Biotech Reports First Quarter 2022 Financial Results
|
English | 36.5 KB | ||
| 2022-05-03 01:21 |
Dr. Bertrand C. Liang and the Company have mutually agreed to terminate his ser…
|
English | 129.6 KB | ||
| 2022-05-03 01:21 |
Dr. Bertrand C. Liang and the Company have mutually agreed to terminate his ser…
|
English | 36.5 KB | ||
| 2022-04-12 01:26 |
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the…
|
English | 171.2 KB |
Automate Your Workflow. Get a real-time feed of all Purple Biotech Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Purple Biotech Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Purple Biotech Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
